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Accepted 30 June 2014; Published online 20 August 2014AbstractObjectives: To compare the accessibility, comprehensiveness, and usefulness of data available from the European Medicines Agency
(EMA) and the Food and Drug Administration (FDA) drug reports.
Study Design and Setting: This is a cross-sectional study. All new molecular drugs approved between January 1, 2011 and December
31, 2012 from the FDA and EMA Web sites were eligible.
Results: We included 27 drug reports. Most were searchable, but the FDA table of contents did not match the file’s page numbers.
Several FDA documents must be searched compared with a single EMA document, but the FDA reports contain more summary data
on harms. Detailed information about harms was reported for 93% of the FDA reports (25 of 27 reports) and 26% of the EMA reports
(7 of 27 reports). The reports contained information about trial methodology but did not include trial registry IDs or investigator names.
All reports but one contained sufficient information to be used in a meta-analysis.
Conclusion: Detailed data on efficacy and harms are available at the two agencies. The FDA has more summary data on harms, but the
documents are harder to navigate. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).
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Doctors and decision makers cannot depend solely on
articles published in medical journals. Articles are often
biased [1,2], and some studies are partially published or
not published at all [3]. Drug regulators have access to
additional data through the companies’ approval applica-
tions, for instance individual patient data on harms and
analysis of efficacy data for multiple outcomes. In the Food
and Drug Administration (FDA) drug reviews, some of
these data are reported and can provide useful unpublished
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0895-4356/Published by Elsevier Inc. This is an open access article under the Cdata can be obtained from FDA and, more recently, the Eu-
ropean Medicines Agency (EMA) websites, they are rarely
used in meta-analysis [9,10]. Difficult access to the FDA
Web site could be part of the explanation [11] and other ex-
planations could be lack of guidance on when and how to
access data from regulators. Both the FDA and the EMA
have made recent changes to the types of information they
make available to the public. The purpose of this study was
to compare the accessibility, comprehensiveness, and use-
fulness of information available on the FDA and EMA
Web sites.2. Methods
We identified all new molecular entities approved by the
FDA from January 1, 2011 to December 31, 2012 through
their Web site (http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm) and paired them with corresponding
EMA drug approvals (http://www.ema.europa.eu). As in
previous studies [7,12], biologics, orphan drugs, and diag-
nostics were excluded because they are reviewed using aC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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 Most FDA and EMA reports described trials in suf-
ficient detail to enable them to be included in a
meta-analysis.
 Most FDA reports contained detailed information
about harms whereas the EMA reports did not.
 The information on the FDA site is harder to navi-
gate, in general, than the information on the EMA
site.
 Both agencies should be searched by researches
conducting reviews.
different approval process. New molecular entities from the
EMAWeb site (http://www.ema.europa.eu) were also iden-
tified in the same time period and paired with the corre-
sponding FDA approval reports.
2.1. General description of drugs and documents
The medical review was our primary FDA resource, but
we also extracted information from the approval letter, the
Risk Evaluation and Mitigation Strategies (REMS), and the
risk assessment reviews when available. For EMA-
approved drugs, we examined only the European public
assessment reports.
To determine how accessible the information was, two
researchers (J.B.S. and M.A.S.) assessed whether each
regulator provided structured reports, number of pages in
the reports, a table of contents, a file that is searchable us-
ing text words, reviews in several languages, and lay sum-
maries and whether it was possible to use direct Web links
to resources.
To estimate how comprehensive the information was, we
assessed whether information was redacted and, if so,
whether a reason for the redaction was given and whether
each regulator reported on unapproved drugs and relayed
internal communications between reviewers and external
communications between the applicant and the agency.
We also assessed if the original trial protocols or the full
trial reports were available and whether the agencies con-
ducted additional statistical analyses.
2.2. Trial characteristics and efficacy data
We assessed the type of trial data that were available
from each regulator and whether useful data for meta-
analysis were available. Two researchers (M.A.S. and
J.B.S.) independently assessed whether the FDA and EMA
reports provided (1) an overview of the pivotal trials (the tri-
als that were the basis of the clinical evaluation of the drug),
(2) summary reports of each pivotal trial, (3) the number of
pivotal trials and other submitted trials included, (4) the
J.B. Schroll et al. / Journal of ClinClinicalTrials.gov ID for each trial, (5) names of the inves-
tigators, and (6) conflicts of interest among investigators.
For the pivotal trials, the two researchers determined
whether the inclusion and exclusion criteria for the trials
were specified, whether outcomes were specified, whether
numerical results were only available in a pooled format,
and whether the efficacy results were presented in a manner
that would allow for their inclusion in a meta-analysis (i.e.,
whether standard deviations and number of individuals were
reported along with the numerical efficacy data).
2.3. Harms data
Two researchers (M.A.S. and J.B.S.) independently
determined whether adverse event tables were present;
whether safety data were provided for all completed trials
or only for the indications being reviewed in the applica-
tion; whether all important harms were reported (defined
as common adverse events, mortality, serious adverse
event, and withdrawals due to adverse events); whether
numerical data on harms were reported; whether a risk
management plan was included; whether regulators
required further studies, follow-up on existing trials, or la-
beling restrictions; and whether REMS (FDA) or educa-
tional materials (EMA) were required by either or both
agencies.
Any discrepancies between the two coders were dis-
cussed with the third author (L.B.). We planned a descrip-
tive analysis of the differences between the data provided
by the EMA and the FDA. We calculated the percentage
of our binary outcomes.3. Results
3.1. Drug characteristics
We found 57 new molecular entities approved by the
FDA between 2011 and 2012; 14 orphan drugs and three
diagnostic drugs were excluded. Another eight drugs were
excluded for not having a corresponding approval on the
EMA Web site (presumably the drug approval was never
pursued in the European Union), four had only a pediatric
plan (which we interpreted as pending), six had a pending
status, and two had been withdrawn by the EMA, leaving
20 pairs approved by both agencies as of August 1, 2013.
A similar search of the EMA Web site identified 50 new
molecular entities approved in the same time period. We
excluded 20 orphan drugs, one diagnostic drug, three with
no FDA matches, two that were not approved by the
FDA, and finally one in which the approval dates between
the two agencies were more than 10 years apart and we
believed that such a comparison would not be fair. The re-
maining 23 pairs identified through the EMA database were
merged with the 20 pairs found in the FDA database to pro-
vide us with a final sample size of 27 unique pairs of drugs
after duplicates were removed (Fig. 1). The most
Fig. 1. Flowchart of included drugs. EMA, European Medicines Agency; FDA, Food and Drug Administration.
104 J.B. Schroll et al. / Journal of Clinical Epidemiology 68 (2015) 102e107commonly approved drugs in our sample were antineo-
plastic drugs (n 5 6) and anti-infective agents (n 5 5).3.2. Accessibility and comprehensiveness of documents
As summarized in Table 1, the FDA medical review
contained substantially more pages than the EMA re-
ports. The FDA reports are structured, but there are often
several versions and updates, whereas the EMA releases
one final document. Only the EMA reports included a ta-
ble of contents at the beginning of every document. The
FDA reports’ typed page numbers did not match the elec-
tronic page numbers. Eight FDA reports were not fully
searchable, the least accessible ones being the oldest
reports.
In the FDA documents, all censored text was obscured,
and the number of redacted pages was specified. The reason
for each redaction was specified; most frequently because it
was considered a trade secret and on a few occasions toprevent investigators and patients from being identified.
Any indications that were not approved were redacted in
FDA reports. EMA reports included a statement on the first
page mentioning that all information of commercial nature
was deleted, but it was not possible to see how much infor-
mation, if any, had been redacted.
Table 1 also summarizes that, although neither of the
agencies provides reports in non-English languages, the
EMA provides a lay summary which is available in several
languages. Letters from the FDA to the applicant are acces-
sible, but communications from the applicants to the FDA
are not. Reports from different departments and senior per-
sonnel’s assessment of reports are only available at the
FDA. Neither of the agencies provides full trial reports or
protocols on their Web sites.
The FDA conducted and included in their reports addi-
tional statistical analyses, whereas the EMA did not. In a
few cases, the FDA also acquired case report forms (indi-
vidual patient data) from the applicants.
Table 1. Characteristics of regulatory reports available for 27 new
drugs approved between 2011 and 2012
Characteristic FDA EMA
Median number of pages (range)a 219 (70e602) 88 (37e133)
Table of contents, % (n) 70 (19)b 100 (27)
Material searchable, % (n) 70 (19) 100 (27)
File partially redacted, % (n) 100 (27) 0 (0)c
Reasons for redaction
indicated, % (n)
96 (26) 100 (27)
Available in several languages, % 0 0
Lay summaries provided, % 0 100
Communication between regulator
and applicant, %
100d 0
Full trial reports available, % 0 0
Trial protocols available, % 0 0
Direct links to relevant reports
can be saved, %
0 100
Abbreviations: EMA, European Medicines Agency; FDA, Food and
Drug Administration.
a For FDA, only the pages from the medical review file were
calculated. Sometimes, this file contained communications and
several versions. The corresponding reports from the EMA also con-
tained information about pharmacology. P-value!0.05 for the Stu-
dent t-test.
b The FDA documents did not contain a table for contents for the
entire document, but they were assessed as acceptable if they had a
table of content for the majority of the document.
c It was unclear for all EMA reports whether anything was redacted
because it was a prepared document for the public. On the first page,
it said that commercial information had been removed but it was not
possible to see how much data (if any) had been removed.
d Redacted only.
Table 2. Characteristics of trials, efficacy, and harms data available for
27 new drugs approved between 2011 and 2012
Characteristic FDA, % (n) EMA, % (n)
ClinicalTrials.gov ID 0 (0) 0 (0)
Summary trial reports of pivotal trials 100 (27) 100 (27)
Names of trial investigators 0 (0) 0 (0)
Patient population specified (inclusion and
exclusion criteria)
96 (26) 96 (26)
Intervention and comparison group specified 89 (24) 93 (25)
Outcomes (endpoints) specified 96 (26) 100 (27)
Total number of patients given 100 (27) 100 (27)
Number of patients for each arm 100 (27) 100 (27)
Numerical results provideddefficacy 100 (27) 100 (27)
Individual trial data provided 100 (27) 100 (27)
Results can be used in a meta-analysis 100 (27) 96 (26)
Harms
Table of common adverse events 96 (26) 67 (18)
Missing trials in safety pool (from other
indications)
4 (1) 0 (0)
All important harms reported 93 (25) 26 (7)
Numerical results provideddharms 100 (27) 100 (27)
Risk management plan and/or
pharmacovigilance
48 (13) 100 (27)
Further trials and/or studies required 78 (21) 48 (13)a
Follow-up existing trials 22 (6) 22 (6)
Labeling restriction 4 (1) 100 (27)
REMS and/or educational material 30 (8) 26 (7)
Abbreviations: EMA, European Medicines Agency; FDA, Food and
Drug Administration; REMS, Risk Evaluation and Mitigation Strategies.
a For additional 10 reports, it was unclear whether further trials
were required or whether the company had voluntarily initiated
them.
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able on the FDAWeb site; however, the EMA provides such
information along with reasons for withdrawal or
nonapproval.
3.3. Trial characteristics and efficacy data
All reports contained an overview of the pivotal trials
with internal trial IDs, but they also listed additional trials
and sometimes what appeared to the whole trial program
with up to 60 trials. This overview was usually in tabular
form and often included study design, intervention,
and location. However, as summarized in Table 2, none
of the trial descriptions contained the corresponding
ClinicalTrial.gov IDs. None of the reports listed all trial
investigator names, although three FDA reports included
names of a few investigators whose sites had been subject
to investigation. The FDA had a ‘‘financial disclosures’’
section which, in 17 of the FDA reports, contained relevant
information on investigator conflicts of interest and in
which the impact on the trials’ outcomes was briefly
discussed.
Table 2 shows that the patient population, the interven-
tion and comparator groups, and the outcomes were
described by both agencies for most drugs.
Table 2 shows that only one EMA report lacked numer-
ical efficacy data and therefore was not suitable for use in ameta-analysis. Standard deviations were missing for indi-
vidual trials.
3.4. Harms data
Nine (33%) EMA reports had no table of common
adverse events, whereas only one (4%) FDA report did not
have this table (Table 2). Only 26% (7 of 27) of the EMA
reports, compared to 93% of the FDA reports, reported all
important information about harms. Compared with the
FDA, the EMA reports contained less summary data on
harms (Table 2). The risk management plan was always
clearly stated in the EMA reports, whereas the FDA relayed
the requirements to industry in the approval letter. The FDA
required additional studies more frequently than the EMA
(Table 2). However, it was primarily the older EMA reports
that did not require additional studies. The EMA reports al-
ways had clearly stated corrections to the label, whereas
such labeling recommendations were either redacted or diffi-
cult to find in the FDA reports. REMS and educational ma-
terials were equally often required by the two agencies.4. Discussion
Drug reviews from the FDA and the EMA can be great
sources of information for clinicians and researchers con-
ducting meta-analyses. Trial methodology was described,
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FDA reports. The FDA provides multiple reports
including statistical analysis, assessments of financial con-
flicts of interest, and sometimes subgroup analysis of
North American patients. The EMA provides a single
report with less information, but it is easier to access
and navigate compared with the FDA. Methods for navi-
gating drug reports are being developed and could ease
handling in the future [13]. Both data sources, but more
frequently the FDA, presented a number of challenges
including redacted information, internal discrepancies,
lack of standardization of reporting, voluminous pages,
and documents that are not fully searchable.
Crucial information about safety concerns and nonap-
proved indications were redacted in the FDA reports.
EMA does not redact descriptions of nonapproved indica-
tions and provides full reports for drugs that were not
approved at all. These are two good reasons for
also searching EMA. Furthermore, the correspondence be-
tween agencies and companies, which is often redacted, is
not merely a simple exchange of facts. Some companies see
it as strategic negotiation which they want to be held confi-
dential from the public although it might be concerning
serious harms [14].
FDA provided information about conflicts of interest,
but only researchers receiving over $25,000/yr are required
to disclose and financial disclosure statements were in some
cases only collected from less than 50% of the
investigators.
Neither the FDA nor the EMA documents make it
easy to use PubMed or other electronic databases to
identify publications that might have resulted from
the trials mentioned in the reviews. Investigator names
are usually not available, the number of trials done
can be difficult to determine, and ClinicalTrials.gov
or other trial registry identifiers are not refer-
enced. ClinicalTrials.gov is another source of unpub-
lished data [15].
A possible explanation for the discrepancies in informa-
tion available is that the two agencies differ substantially in
their structure and the laws governing their functions
[16e19]. The documents produced by the agencies are
not intended for research synthesis, and this is another
important reason why information that a reviewer would
find essential might not be available. Full clinical study re-
ports which are included in the companies’ approval appli-
cations would provide an even better understanding of
drugs, but they are currently not readily available and
require considerable time and resources to extract useful
data [20].4.1. Limitations
Some of our assessments involved some amount of
subjectivity, but we attempted to minimize this limitation
by having two coders. In documents that were notsearchable, we could have overlooked information because
of the large number of pages. Although our sample was
small, it was a comprehensive sample of new drugs that
were recently approved by both the agencies through the
standard approval process. We have excluded orphan drugs
and biologics which do not go through the standard
approval process, so our results cannot be extrapolated to
these drugs.5. Conclusion
The FDA and EMA summary reports contained data that
can be used for clinical decision making and meta-analysis.
Data on harms are more detailed in the FDA reports,
whereas the EMA reports are easier to use and sufficient
for the collection of efficacy data.Acknowledgments
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